Tezepelumab PRO study

Trial Identifier: D5180R00025
Sponsor: AstraZeneca
NCTID:: NCT05922891
Start Date: September 2023
Primary Completion Date: September 2025
Study Completion Date: September 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aomori, Japan
Japan Bunkyo, Japan
Japan Fujisawa, Japan
Japan Fukuoka, Japan
Japan Fukushima, Japan
Japan Hamamatsu, Japan
Japan Hiroshima, Japan
Japan Iizuka, Japan
Japan Itabashi, Japan
Japan Izumo, Japan
Japan Kawasaki, Japan
Japan Kitakyushu, Japan
Japan Kiyose, Japan
Japan Kurashiki, Japan
Japan Matsusaka, Japan
Japan Minami, Japan
Japan Minato, Japan
Japan Nagakute, Japan
Japan Nagoya, Japan
Japan Naka, Japan
Japan Niigata, Japan
Japan Nishinomiya, Japan
Japan Osaka, Japan
Japan Sapporo, Japan
Japan Shinagawa, Japan
Japan Shinjuku, Japan
Japan Sizuoka, Japan
Japan Tennoji, Japan
Japan Ube, Japan
Japan Yonago, Japan